Roth Capital Has Positive View of Globus Medical Q4 Earnings

Globus Medical, Inc. (NYSE:GMED) – Investment analysts at Roth Capital raised their Q4 2025 earnings per share (EPS) estimates for Globus Medical in a research note issued to investors on Monday, December 16th. Roth Capital analyst J. Wittes now forecasts that the medical device company will post earnings of $0.96 per share for the quarter, up from their previous forecast of $0.91. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share.

GMED has been the topic of several other reports. Canaccord Genuity Group lifted their price target on shares of Globus Medical from $85.00 to $92.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Roth Mkm boosted their target price on Globus Medical from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday. Royal Bank of Canada increased their price target on Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th. Bank of America upped their price objective on shares of Globus Medical from $55.00 to $80.00 and gave the company an “underperform” rating in a report on Wednesday, November 6th. Finally, BTIG Research lifted their price objective on shares of Globus Medical from $87.00 to $91.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and a consensus target price of $94.55.

Globus Medical Stock Up 0.8 %

NYSE GMED opened at $82.63 on Thursday. Globus Medical has a 52 week low of $49.33 and a 52 week high of $87.22. The company has a 50 day moving average price of $80.02 and a 200 day moving average price of $73.34. The firm has a market cap of $11.25 billion, a PE ratio of 123.33, a price-to-earnings-growth ratio of 1.99 and a beta of 1.19.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.65 by $0.18. The company had revenue of $625.71 million for the quarter, compared to the consensus estimate of $604.69 million. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. Globus Medical’s quarterly revenue was up 63.1% on a year-over-year basis. During the same period last year, the business posted $0.57 EPS.

Insiders Place Their Bets

In other Globus Medical news, SVP Kelly Huller sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total transaction of $217,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel T. Scavilla sold 60,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total value of $4,801,200.00. The disclosure for this sale can be found here. Insiders have sold 97,500 shares of company stock worth $7,674,950 over the last ninety days. Corporate insiders own 18.54% of the company’s stock.

Institutional Investors Weigh In On Globus Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Select Equity Group L.P. purchased a new stake in Globus Medical during the 2nd quarter valued at approximately $91,711,000. Millennium Management LLC lifted its stake in shares of Globus Medical by 1,171.5% in the second quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock valued at $93,409,000 after purchasing an additional 1,256,570 shares during the period. ArrowMark Colorado Holdings LLC purchased a new stake in Globus Medical during the third quarter worth about $43,947,000. Lord Abbett & CO. LLC acquired a new stake in shares of Globus Medical in the 3rd quarter worth approximately $37,948,000. Finally, Parsifal Capital Management LP increased its stake in Globus Medical by 50.5% in the 3rd quarter. Parsifal Capital Management LP now owns 1,350,553 shares of the medical device company’s stock valued at $96,619,000 after purchasing an additional 453,053 shares in the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.